Skip to search formSkip to main contentSkip to account menu

IDN 5109

Known as: IDN5109, IND5109 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Recent advances in the design and preclinical evaluations of promising new generation taxane anticancer agents are reviewed in… 
Review
2002
Review
2002
Abstract Paclitaxel (Taxol®) and docetaxel (Taxotère®) are currently two of the most important anticancer drugs in cancer… 
Review
2002
Review
2002
P‐glycoprotein (P‐GP)‐based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clinical use… 
2001
2001
PURPOSE Protein kinase A type I (PKAI) and the epidermal growth factor receptor (EGFR) play a role in neoplastic transformation… 
2001
2001
By flexibly docking 9593 compounds of the NCI-3D database against the refined structure of beta-tubulin using DOCK 4.0, a long… 
Highly Cited
2000
Highly Cited
2000
IDN5109 is a new taxane, derived from 14beta-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor… 
Highly Cited
1999
Highly Cited
1999
Clinically available taxanes represent one of the most promising class of antitumor agents, despite several problems with their…